Stem Cell Innovations and High Q Foundation Collaborate to Develop Novel Models of Huntington's Disease
News Jun 26, 2007
The High Q Foundation Inc. (High Q) and Stem Cell Innovations, Inc. (SCI) announced that they have entered into a two-year R&D alliance. The organizations will apply SCI's PluriCells™ to develop Huntington's disease specific human cell systems for the purpose of drug discovery.
Under the terms of their agreement, SCI will receive up to $1.1 million from High Q upon completion of certain milestones. In addition, SCI has the right to further use, develop and commercialize the outcome of the project.
"We are extremely pleased to enter this significant collaboration with the High Q, a leader in the support of research aimed at combating Huntington's disease. This agreement will allow us to accelerate our efforts in generating a unique panel of human neurodegenerative disease models, which will be integral in the further development of our potential products," said Stem Cell Innovations' CEO Dr. James Kelly.
"Huntington's disease represents a great unmet medical need and SCI is proud to assist High Q with its search to treatments that prevent or slow its progression," Kelly continued.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019